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The inﬂammatory bowel diseases (IBDs) are chronic inﬂammatory processes aﬀecting the gastrointestinal tract. When diagnosed
in childhood and adolescence, IBD almost always impacts adversely upon the nutritional state of the patient. Weight loss and
impaired linear growth may be present at diagnosis or subsequently. Further potential nutritional consequences in childhood IBD
include malnutrition, anaemia, osteopaenia, and delayed puberty. Understanding the nutritional aspects of IBD is paramount in
growing children, especially those entering and advancing through puberty. This paper focuses upon the nutritional impacts of
IBD in children and adolescents.
1.Introduction
The inﬂammatory bowel diseases (IBDs) are chronic ill-
nessesaﬀectingthegastrointestinaltract:theypredominantly
comprise Crohn’s disease (CD) and ulcerative colitis (UC).
Although CD and UC share some features, they have
distinctive endoscopic and histological characteristics and
disease patterns [1]. Furthermore, the clinical manifestations
and outcomes of these two conditions vary. At present,
there are no speciﬁc medical cures for CD and UC: current
therapies aim to control the disease and prevent adverse
outcomes [1].
CD and UC may present at any age. Although IBD
is uncommon in the ﬁrst decade of life, presentation in
infancy is well recognized. IBD is more common in the
second decade, particularly in adolescence [2, 3]. There are
clear demonstrations of increasing incidence of IBD around
the world over the last decades, with increased rates also
noted in areas with previous very low rates [3–8]. The
changing incidence of IBD has also been noted in paediatric
populations, with particular increases in CD [9, 10].
A history of weight loss or poor weight gain is commonly
recorded at the time of diagnosis with IBD in children and
adolescents. Poor linear growth may also be evident at the
initial assessment, leading to growth failure in some. Growth
impairment is typically more prominent in CD than UC
[1]. Impaired nutrition may lead onto short- and long-term
consequences that include delayed puberty, micronutrient
deﬁciencies, impaired adult height, and bone disease. Regu-
lar monitoring and detailed attention to nutritional support
remains a central facet of the management of children and
adolescents with IBD. This paper will focus on the impact of
IBD upon the nutritional state of children and adolescents
and will highlight recent advances in this area.
2.AlteredGrowthPatternsinPaediatricIBD
2.1. Weight in Children with IBD. Numerous cohort studies
have demonstrated weight loss or poor weight gains at the
time of initial diagnosis of IBD. Reports indicate that most
children with CD have a history of weight loss or absent
weight gains prior to diagnosis. In a cohort of 386 Canadian
children diagnosed with CD over a ten-year period, 80%
had a history of weight loss [1] .Ar e t r o s p e c t i v ec h a r tr e v i e w
of a cohort of 61 children diagnosed with CD at Sydney
Children’s Hospital, Sydney, Australia showed that 51% had
a history of weight loss at the time of diagnosis [11]. In a
prospectiveUKstudyof379paediatricCDpatients,58%had2 ISRN Pediatrics
weight loss at diagnosis and 27% had weight < 3rd centile
[12]. Weight loss tends to be seen less commonly in children
with UC—up to 31% of 172 children in the same UK cohort
had a history of weight loss at diagnosis [12].
Maintaining appropriate weight gainalsocontinues tobe
an ongoing issue after diagnosis. In a cohort of 41 children
with longstanding CD recruited to assess dietary intakes and
nutrition, the 18 children with active CD had lower mean
Z scores for weight, height, and BMI than the 23 children
currently in remission [13].
The reasons for altered weight gains are likely multifac-
torial, with decreased caloric intake being the most common
[14–19]. Poor intake may be the consequence of the anorexic
eﬀects of proinﬂammatory mediators, such as interleukin-
1β or Tumour necrosis factor (TNF)-α [20, 21]o rr e s u l t
from early satiety, pain, or nausea. Pain associated with
eating, leading to poor tolerance of foods, and the fear of
diarrhoea following meals are additional reported reasons
for reduced intake. Small bowel involvement may lead
to disaccharide intolerance resulting in shorter gut transit
times,pain,andexacerbationofdiarrhoea.Malabsorptionof
food components and the diversion of calories to sites of gut
inﬂammation may be further contributing factors leading to
impaired growth.
2.2. Impaired Linear Growth in IBD. In addition to presenta-
tion with loss of body weight or poor weight gains, children
also commonly have altered patterns of linear growth.
Decreased height velocity was noted in up to 88% of a group
of 50 children at the time of diagnosis with CD—a number
of these children had impaired linear growth prior to the
onset of gut symptoms [22]. Impaired linear growth tends to
be more pronounced in boys than girls—this is principally
related to the male pubertal growth spurt occurring later and
lasting longer. Boys may also be more aware of variations in
height. Furthermore, the limited duration of puberty limits
the time before impaired linear growth becomes irreversible
[23, 24].
CD is commonly associated with impaired linear growth
either at diagnosis or as a long-term outcome [22–29].
Someearlierstudiesreportedthatdespitegrowthretardation
occurring during teenage years, many of these patients
eventually achieved heights within the normal range for the
generalpopulation [30,31];however,the geneticcomponent
of linear growth was not considered in these studies.
Markowitz et al. [24] retrospectively assessed the growth
patterns of 48 adults with IBD (38 with CD and 10 with
UC: 73% male) who had previously been diagnosed during
childhood. These investigators used two height prediction
methods and employed the American National Centre for
HealthStatisticsgrowthcharts:31%ofthisgroupwerefound
to have permanently impaired linear growth. In their study
of 132 children and young adults aged between 5–25 years,
Sentongo and colleagues [28] argued that height adjusted for
geneticpotentialwasamorepowerfulwayofassessingheight
status in children with CD. In these children, the Z scores
based on adjusted heights were signiﬁcantly lower than Z
scores based on measured heights. Again, males in this group
were most severely aﬀected, with the average adjusted height
for age Z score one standard deviation less than expected.
Lee et al. [30] recently undertook a prospective assess-
ment of height in 295 children with CD and UC who had
been diagnosed between 2002 and 2008 in Boston, USA.
Twenty-two percent of these children (90% of whom had
CD) had linear growth impairment (height for age Z-score
of −1.64 or less) documented on one or more measurements
from the time of diagnosis. The ﬁnal mean adult height Z
score in this cohort was −0.39.The main predictors of ﬁnal
adult height in this cohort were found to be lower parental
height and the patient’s lowest height Z score.
A recent British study also assessed the ﬁnal adult height
of a group of 23 individuals who had been diagnosed with
CD prior to their 16th birthday [31]. This group had a ﬁnal
adult height Z score of −0.29: very similar to that observed
in the North American study [30] .T h em e a nﬁ n a lh e i g h t
of these patients was 2.4cm less than the parental or target
height (range of −20.0 to +9.0cm). Twenty percent of the
grouphadaﬁnaladultheightgreaterthan8.0cmbelowtheir
target height. Jejunal disease and the length of symptoms
prior to diagnosis (diagnostic delay) were predictive factors
of ﬁnal adult height in this cohort. In this cohort, exposure
to corticosteroids, surgical intervention, and parental height
were not predictive factors. Jejunal disease location has
previouslybeensuggestedtobeassociatedwithlineargrowth
impairment [32, 33].
A Danish population-based assessment of growth in
children with IBD highlights the diﬀerential eﬀects of CD
andUCupongro wth[34].Forty-fourchildrenwithCDwere
included in this study, along with 50 with UC and four with
IBD unclassiﬁed (IBDU). The growth data was normalised
using Danish reference values. The children with UC had
similar height and BMI scores for age to control data. In
contrast, the children with CD had height for age Z score
of −0.77: also they were shorter than the children with UC
(P = .005).FiftypercentofthechildrenwithCDhadaheight
less than the 25th centile for age.
2.3. Factors Inﬂuencing Linear Growth in Children with IBD.
Numerous factors impact upon impaired linear growth in
IBD. Several gut-derived mediators likely impact negatively
upon linear growth [35]. TNF-α inhibits chondrocyte activ-
ity in growth plates [36]. Interleukin (IL)-6 may have direct
eﬀects leading to growth failure [37]. Elegant studies in
rodent models show that approximately 40% of growth
impairment is consequent to the eﬀects of inﬂammatory
proteins, especially IL-6 [38, 39]. Further, TNF-α and IL-6
both independently suppress levels of Insulin-like Growth
Factor (IGF)-1, a critical mediator of the local actions of
growth hormone [40].
Male gender, age at diagnosis, disease location, disease
severity, and treatment modality may also all aﬀect ﬁnal
height acquisition. Severity of disease (deﬁned by various
measures such as steroid requirements, use of immuno-
suppressives, and cumulative period of hospitalisation) was
correlated with impaired weight and height gains in a cohort
of Israeli children [41]. Location of disease in these childrenISRN Pediatrics 3
wasalsoweaklyassociatedwithgrowthimpairment.Interest-
ingly, the presence of the NOD2 genotype was not associated
with impaired weight or linear growth, despite associations
between ileal location and mutations in this gene.
A recent report highlighted the importance of genetic
inﬂuences upon linear growth in children with IBD. In
a cross-sectional study, 951 subjects, comprising 317 CD
patient-parent trios, were genotyped for growth-associated
genetic loci and CD-associated loci [42]. Linear growth
impairment in the children with CD was associated with a
polymorphism in the dymeclin gene DYM (Odds Ratio 3.2).
2.4. Pubertal Delay in IBD. Delayed puberty is also fre-
quently observed in children with IBD, especially those with
CD [43, 44]. In one cohort of children diagnosed with CD
prior to the onset of puberty, menarche was noted to occur
at or later than 16 years of age in almost three-quarters of the
girls[43].Delayedpubertaldevelopmentismorecommonin
childrenwhohaveneverachievedremissionorwhohavehad
repeated disease relapses [44], emphasizing the interactions
between disease control and growth in children.
2.5. Overweight and Obesity in IBD. Although the most
concern in regard to the nutritional impact of IBD in
children is towards under nutrition, some children with IBD
maybeoverweight(BMI>85%)and/orobese(BMI>95%).
In a cohort of 166 children with newly diagnosed IBD from
Wisconsin,USA,12.1%ofthosewithCDand17.6%ofthose
with UC were overweight/obese [45].
In a group of 1598 American children with known IBD,
the prevalence of overweight and obese status was found to
be 23.3% overall [46]. A higher rate (30%) was also seen
in the UC group. Overweight/obesity in this multicentre
cohort was associated with African-American ethnicity and
Medicaid insurance status. In addition, a prior surgical
intervention was linked with overweight/obese status in
the children with CD, suggesting that the presence of over
nutrition may be associated with a more severe disease
course.
2.6. Inﬂuence of Medical Therapies upon Growth in Children
with IBD. Medical therapies may impact negatively upon
aspects of growth in children with IBD. Corticosteroids,
for example, can lead to numerous side eﬀects, includ-
ing nutritional consequences [47]. Increased appetite and
ﬂuid retention are commonly seen after commencement of
steroids. Consequently, apparent improvements in weight
during a course of corticosteroids may reﬂect ﬂuid retention
andnotanimprovementintheunderlyingnutritionalstatus.
Steroidsalsoleadtoenhancedboneresorptionanddecreased
new bone formation, adversely aﬀecting bone health [48,
49]. Further, daily corticosteroid therapy can suppress IGF-
1 activity, contributing to inhibition of linear growth and
impaired ﬁnal height [50].
Some medical therapies may compromise micronutrient
status. Sulphasalazine may lead to folate malabsorption;
however, daily folate supplementation does not appear
necessary [51]. Folate supplementation is required, however,
when Methotrexate is used to avoid folate deﬁciency due to
the inhibition of the conversion of folate to the active moiety
tetrahydrofolate [52]. Cholestyramine, when required for
bile-salt diarrhea, may impede absorption of vitamin B12.
In contrast, some interventions, such as exclusive enteral
nutrition (EEN) and biological therapies, have numerous
positive nutritional eﬀects. EEN is a speciﬁc nutritional
therapy that involves the administration of a liquid formula
as sole nutritional intake (with exclusion of normal diet)
for up to 8 weeks [53]. This therapy is eﬃcacious in
active CD, with remission rates similar to those seen with
corticosteroids [54]. EEN leads to positive improvements in
weight and linear growth, normalization of IGF-1 levels, and
stabilization of bone turnover [53]. EEN is also associated
with improved vitamin D status compared to children
treated with corticosteroids [55].
Biological therapies in children with CD also clearly
impact positively upon growth [56–60]. Walters et al. [58]
examined the growth patterns of 32 children treated with
Inﬂiximab (28 responders) for severe CD. These children
had improved height velocity, and height centile increases
after Inﬂiximab, with timing prior to early puberty being
important. Malik et al. [59] found that improvements
in linear growth after Inﬂiximab can be independent of
pubertalstatusandreductionincorticosteroids.Theseeﬀects
of inﬂiximab in children with CD may be due to improved
inﬂammation with mucosal healing or due to direct eﬀects
upon growth hormone and IGF-1 signaling [60]. In a recent
report, Cromb´ e et al. [61] demonstrated that the height
Z scores of a group of 41 French children responding to
Inﬂiximab improved from −0.57 ± 1.18 to −0.25 ± 0.99
(P = .04) over the period of followup. In contrast, those
childrennotrespondingtothisdrughadnocatchupgrowth.
2.7. General Management of Growth in Children with CD.
Given the frequency and patterns of disturbed growth in
children with IBD (and especially those with CD), the
management of such children must include a clear and
constant focus upon growth and nutrition. Resumption of
normal growth patterns should be seen as an element of the
success of therapy.
Baseline assessment of nutritional status at the time
of diagnosis should include detailed standard anthropom-
etry, along with clear documentation of preceding growth
patterns and familial growth patterns (especially parental
heights). Furthermore, close monitoring of growth during
followup must be considered a mandatory part of the
multidisciplinary care of children and adolescents with IBD.
3. Conclusion
Thereisnowplentifulevidencedemonstratingthesigniﬁcant
impact of IBD upon growth and nutrition in children.
Recent studies have helped to demonstrate the importance
of nutritional, inﬂammatory, and genetic factors in growth
outcomes. Consequently, a key aspect of the ongoing man-
agement of children and adolescents with IBD should be the
close and constant attention to growth.4 ISRN Pediatrics
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